Skip to Content
Merck

[A review of pharmacological studies on nicergoline].

Arzneimittel-Forschung (1979-01-01)
A Moretti, G Arcari, L Pegrassi
PMID44197
ABSTRACT

10-Methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) shows a strong alpha-blocking activity both in vitro and in vivo. Various studies (dog, cat, rabbit, rat, mouse, guinea-pig) show that nicergoline affects only slightly blood pressure and heart rate and increases the blood flow in brain and hind limb without affecting the splanchnic and aortic flow in normal animals. Nicergoline does not interfere with CNS functions unless applied in high doses. It stimulates the muscle oxidative metabolism and function and lacks any emetic and hallucinogenic activity. Its acute and chronic toxicity in different animal species is very low.

MATERIALS
Product Number
Brand
Product Description

Nicergoline for system suitability, European Pharmacopoeia (EP) Reference Standard
Nicergoline for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Nicergoline, analytical standard, for drug analysis
Nicergoline, European Pharmacopoeia (EP) Reference Standard